Harrow Health, Inc. cash flow to debt ratio of 17.41% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Harrow Health, Inc.'s free cash flow has increased -170.24% from $-60.88M last year to $42.76M, signaling increasing performance

Harrow Health, Inc.'s debt to equity ratio is 10.47, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Harrow Health, Inc.'s debt has increased relative to shareholder equity from 3.29 last year to 10.47 today, signaling weakened financials

Harrow Health, Inc. has a net debt to EBITDA ratio of 4.33x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Harrow Health, Inc.'s interest coverage ratio is 1.22, which means that the company struggles to meet interest obligations, signaling financial risk.

Harrow Health, Inc.'s profit margin has increased (-36.41%) in the last year from -8.76% to -5.57%, signaling increasing performance

Harrow Health, Inc.'s short-term assets of $211.75M exceed its short-term liabilities of $96.30M

Harrow Health, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Harrow Health, Inc.'s return on equity of -33.65%, is lower than 15.00%, indicating bad performance

Harrow Health, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Harrow Health, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Harrow Health, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Harrow Health, Inc. has a free cash flow yield of 2.73%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Harrow Health, Inc.'s yearly earnings has increased -70.60% since last year from $-17.48M to $-5.14M, signaling increasing performance

Harrow Health, Inc.'s yearly revenue has increased 36.41% since last year from $199.61M to $272.30M, signaling increasing performance

ROIC 8.55% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Harrow Health, Inc.'s 3-year revenue CAGR of 45.39% is positive, indicating growing revenue over the past 3 years

Harrow Health, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Harrow Health, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Harrow Health, Inc. has insufficient data to evaluate this check.

Harrow Health, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Harrow Health, Inc. is overvalued relative to its fair value price of 5.74 based on EBITDA multiple model

Harrow Health, Inc. has an EV/EBITDA ratio of 56.38x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Harrow Health, Inc. is overvalued relative to its fair value price of 3.71 based on Earnings Fair Value model

Harrow Health, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Harrow Health, Inc. has a price-to-book ratio of 54.56x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Harrow Health, Inc. has a price-to-sales ratio of 5.84x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue